Biochemical and aggregation analysis of Bence Jones proteins from different light chain diseases

Amyloid

Volumn 15, Issue 1, 2008, Pages 29-39

  Sikkink, Laura A ^a   Ramirez Alvarado, Marina ^a  

^a MAYO CLINIC   (United States)

Author keywords

Aggregates; Amyloid; Circular dichroism; Electron microscopy; Fibrils; Light chain amyloidosis; Light chain deposition disease; Multiple myeloma

Indexed keywords

BENCE JONES PROTEIN; IMMUNOGLOBULIN LIGHT CHAIN;

AMYLOIDOSIS; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN FOLDING; PROTEIN SECONDARY STRUCTURE; PROTEIN STABILITY; STRUCTURE ANALYSIS; THERMODYNAMICS;

AMYLOIDOSIS; BENCE JONES PROTEIN; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MULTIPLE MYELOMA; PROTEIN FOLDING; PROTEIN STRUCTURE, SECONDARY; THERMODYNAMICS;

EID: 39049154947     PISSN: 13506129     EISSN: 17442818     Source Type: Journal    
DOI: 10.1080/13506120701815324     Document Type: Article

References (29)

1. Roussel A, Spinelli S, Deret S, Navaza J, Aucouturier P, Cambillau C. The structure of an entire noncovalent immunoglobulin kappa light-chain dimer (Bence-Jones protein) reveals a weak and unusual constant domains association. Eur J Biochem 1999;26:192-199.
2. Gertz MA, Lacy MQ, Dispenzieri A. Amyloidosis. Hematol Oncol Clin North Am 1999;13:1211-1233.
3. Sezer O, Eucker J, Schmid P, Possinger K. New therapeutic approaches in primary systemic AL amyloidosis. Ann Hematol 2000;79:1-6.
4. Royer B, Arnulf B, Martinez F, Roy L, Flageul B, Etienne I, Ronco P, Brouet JC, Fermand JP. High dose chemotherapy in light chain or light and heavy chain deposition disease. Kidney Int 2004;65:642-648.
5. Wetzel R. Domain stability in immunoglobulin light chain deposition disorders. Adv Protein Chem 1997;50:183-242.
6. Abraham RS, Geyer SM, Price-Troska TL, Allmer C, Kyle RA, Gertz MA, Fonseca R. Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). Blood 2003;101:3801-3803.
7. Stevens FJ, Weiss DT, Solomon A. Structural bases of light chain-related pathology. In: Zanetti M, Capra JD, editors. The Antibodies, Vol. 5. Harwood Academic Publishers; 1999. pp 175-208.
8. Buxbaum J. Mechanisms of disease: monoclonal immunoglobulin deposition. Amyloidosis, light chain deposition disease, and light and heavy chain deposition disease. Hematol Oncol Clin North Am 1992;6:323-346.
9. Hurle MR, Helms LR, Li L, Chan W, Wetzel R. A role for destabilizing amino acid replacements in light-chain amyloidosis. Proc Natl Acad Sci USA 1994;91:5446-5450.
10. Perfetti V, Ubbiali P, Vignarelli MC, Diegoli M, Fasani R, Stoppini M, Lisa A, Mangione P, Obici L, Arbustini E, Merlini G. Evidence that amyloidogenic light chains undergo antigen-driven selection. Blood 1998;91:2948-2954.
11. Pace CN, Scholtz M. Measuring the conformational stability of a protein. In: Creighton TE, editor. Protein Structure A Practical Approach. 2nd ed. New York: Oxford University Press; 1997. pp 299-321.
12. Khurana R, Gillespie JR, Talapatra A, Minert LJ, Ionescu-Zanetti C, Millett I, Fink AL. Partially folded intermediates as critical precursors of light chain amyloid fibrils and amorphous aggregates. Biochemistry 2001;40:3525-3535.
13. Ramirez-Alvarado M, Cocco MJ, Regan L. Mutations in the B1 domain of protein G that delay the onset of amyloid fibril formation in vitro. Protein Sci 2003;12:567-576.
14. Ramirez-Alvarado M, Merkel JS, Regan L. A systematic exploration of the influence of the protein stability on amyloid fibril formation in vitro. Proc Natl Acad Sci USA 2000;97:8979-8984.
15. Bellotti V, Stoppini M, Mangione PP, Fornasieri A, Min AL, Merlini G, Ferri G. Structural and functional characterization of three human immunoglobulin k light chains with different pathological implications. Biochim Biophys Acta 1996;1317:161-167.
16. Wall J, Schell M, Murphy C, Hrncic R, Stevens FJ, Solomon A. Thermodynamic instability of human lambda 6 light chains: correlation with fibrillogenicity. Biochemistry 1999;38:14101-14108.
17. Kim Y, Wall JS, Meyer J, Murphy C, Randolph TW, Manning MC, Solomon A, Carpenter JF. Thermodynamic modulation of light chain amyloid fibril formation. J Biol Chem 2000;275:1570-1574.
18. Goto Y, Fink AL. Conformational states of beta-lactamase: molten-globule states at acidic and alkaline pH with high salt. Biochemistry 1989;28:945-952.
19. Semisotnov GV, Rodionova NA, Razgulyaev OI, Uversky VN, Gripas AF, Gilmanshin RI. Study of the "molten globule" intermediate state in protein folding by hydrophobic fluorescent probe. Biopolymers 1991;31:119-128.
20. Fink AL. 8-Anilinonaphthalene-1-Sulfonic Acid. In: Creighton TE, editor. The Encyclopedia of Molecular Biology. New York: John Wiley and Sons; 1999. pp 140-142.
21. Ramirez-Alvarado M, Regan L. Does the location of a mutation determine the ability to form amyloid fibrils? J Mol Biol 2002;323:17-22.
22. Lakowicz JR. Protein Fluorescence. Principles of Fluorescence Spectroscopy, 2nd ed. New York: Plenum Publishing Corporation; 1999. pp 445-486.
23. Makin OS, Serpell LC. Examining the structure of the mature amyloid fibril. Biochem Soc Trans 2002;20:521-525.
24. Souillac PO, Uversky VN, Millett IS, Khurana R, Doniach S, Fink AL. Effect of association state and conformational stability on the kinetics of immunoglobulin light chain amyloid fibril formation at physiological pH. J Biol Chem 2002;277:12657-12665.
25. Souillac PO, Uversky VN, Millett IS, Khurana R, Doniach S, Fink AL. Elucidation of the molecular mechanism during the early events in immunoglobulin light chain amyloid fibrillation. Evidence for an off- pathway oligomer at acidic pH. J Biol Chem 2002;277:12666-12679.
26. Souillac PO, Uversky VN, Fink AL. Structural transformations of oligomeric intermediates in the fibrillation of immunoglobulin light chain LEN. Biochemistry 2003;42:8094-8104.
27. Vidal R, Goni F, Stevens F, Aucouturier P, Kumar A, Frangione B, Ghiso J, Gallo G. Somatic mutations of the L12a Gene in V-k1 light chain deposition disease potential effects on aberrant protein conformation and deposition. Am J Pathol 1999;155:2009-2017.
28. Ramirez-Alvarado M, De Stigter JK, Baden EM, Sikkink LA, McLaughlin RW, Taboas A. Immunoglobulin light chain and systematic AL amyloidosis. In: Uversky VN, Fink AL, editors. Protein Misfolding, Aggregation and Conformational Diseases Part B: Molecular Mechanisms of Conformational Diseases. New York: Springer; 2007. pp 183-197.
29. Branden C, Tooze J. Introduction to protein structure. New York: Garland Publishing Inc.; 1999. p 410.